Real-world Data on the Diagnosis, Treatment and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT study

Abstract

Introduction: Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide. While there has been rapid evolution in the treatment paradigm of HCC across the past decade, the extent to which these newly approved therapies are utilised in clinical practice in the real world is however, unknown. The INSIGHT study was an investigator-initiated, multi-site longitudinal cohort study conducted to reflect real-world epidemiology and clinical practice in Asia-Pacific in the immediate 7-year period after the conclusion of the BRIDGE study. Methods: Data was collected both retrospectively (planned 30% of total cohort size) and prospectively (planned 70%) from January 2013 to December 2019 from eligible patients newly diagnosed with HCC from 33 participating sites across 9 Asia-Pacific countries. Results: A total of 2,533 newly diagnosed HCC patients (1052 in retrospective cohort and 1481 in prospective cohort) were enrolled. The most common risk factor was hepatitis B in all countries except Japan, Australia and New Zealand, where the prevalence of Hepatitis C and diabetes were more common. The top three comorbidities reported in the INSIGHT study include cirrhosis, hypertension and diabetes. We observe high heterogeneity in the first-line treatment recorded across countries and across disease stage, which significantly affects survival outcomes. Stratification by factors such as etiologies, tumor characteristics, presence of extrahepatic metastases or macrovascular invasion and the use of subsequent lines of treatment were performed. Conclusion: The INSIGHT study describes a wide spectrum of clinical management practices in HCC, where patient demographics, differential costs and patient access to therapies may lead to wide geographical variations through the patient’s treatment cycle, from diagnosis to clinical outcome. The high heterogeneity in patient outcomes demonstrates the need for more robust and clinical management strategies to be designed and adopted to bring about better patient outcomes.